Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Top Cited Papers
- 1 December 2016
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (12) , e542-e551
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?Scientific Reports, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Exploiting the Mutanome for Tumor VaccinationCancer Research, 2012
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingNature, 2012
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJournal of Translational Medicine, 2011
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010